Technology
Technology Platform

UniXell's innovative reprogramming technology platform, stem cell differentiation platform, high-precision gene editing platform and SISBAR pedigree tracing technology create infinite possibilities for cell therapy.

R&D pipeline

Utilizing our well established technology platforms of human pluripotent stem cell preparation, culture, differentiation and gene editing , UniXell is committed to the research and product development in the field of stem cell therapy, especially for neurodegenerative diseases.

  • R&D pipeline
    Indication
    Cell products
    R&D
    CMC
    Preclinical
    IND
    Phase 1
    Phase 2/3
  • UX-DA001
    Parkinson’s Disease
    Midbrain dopaminergic
    progenitor cells
    Parkinson’s Disease

  • UX-EP001
    Epilepsy
    GABA progenitor cells
    Epilepsy

    Medial temporal lobe epilepsy (MTLE), which is characterized by hippocampal sclerosis with neuronal loss, tissue damage and gliosis, is the most common form of focal epilepsies in adults (around 70%).  A considerable fraction of patients with MTLE are refractory to antiepileptics and not suitable for surgery. UniXell's strategy for MTLE is the most promising cell therapy. We manufacture the GABAergic progenitors from human pluoripotent stem cells. After transplanted into hippocampus of patients, the progenitors mature into GABA neurons, which establish synaptic connections with host neurons, restore neural circuitry,  rebanlance the excitory and inhibitory networks in host brain and mitigate epileptic seizures while still maintain the important functions of hippocampus.

  • UX-HE001
    Hypoxic-ischemic
    Encephalopathy
    GABA progenitor cells
    Hypoxic-ischemic
    Encephalopathy

  • UX- SP001
    Spinal Cord Injury
    Spinal cord Neural
    progenitor Cells
    Spinal Cord Injury

  • UX-UD
    Undisclosed
    Undisclosed
    Undisclosed

XML 地图 | Sitemap 地图